CR20170296A - Métodos para el desarrollo y uso de unidades de micro-agregados de células funcionales mínimamente polarizadas en aplicaciones de tejidos utilizando células madre epiteliales que expresan lgr4, lgr5 y lgr6 - Google Patents

Métodos para el desarrollo y uso de unidades de micro-agregados de células funcionales mínimamente polarizadas en aplicaciones de tejidos utilizando células madre epiteliales que expresan lgr4, lgr5 y lgr6

Info

Publication number
CR20170296A
CR20170296A CR20170296A CR20170296A CR20170296A CR 20170296 A CR20170296 A CR 20170296A CR 20170296 A CR20170296 A CR 20170296A CR 20170296 A CR20170296 A CR 20170296A CR 20170296 A CR20170296 A CR 20170296A
Authority
CR
Costa Rica
Prior art keywords
applications
tisseu
funcrion
expresing
develoment
Prior art date
Application number
CR20170296A
Other languages
English (en)
Spanish (es)
Inventor
Denver M Lough
Original Assignee
Polarityte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56078499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20170296(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polarityte Inc filed Critical Polarityte Inc
Publication of CR20170296A publication Critical patent/CR20170296A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/362—Skin, e.g. dermal papillae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
CR20170296A 2014-12-02 2015-12-01 Métodos para el desarrollo y uso de unidades de micro-agregados de células funcionales mínimamente polarizadas en aplicaciones de tejidos utilizando células madre epiteliales que expresan lgr4, lgr5 y lgr6 CR20170296A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086526P 2014-12-02 2014-12-02
US14/954,335 US10926001B2 (en) 2014-12-02 2015-11-30 Methods related to minimally polarized functional units
PCT/US2015/063114 WO2016089825A1 (en) 2014-12-02 2015-12-01 Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using lgr4, lgr5 and lgr6 expressing epithelial stem cells

Publications (1)

Publication Number Publication Date
CR20170296A true CR20170296A (es) 2018-01-25

Family

ID=56078499

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170296A CR20170296A (es) 2014-12-02 2015-12-01 Métodos para el desarrollo y uso de unidades de micro-agregados de células funcionales mínimamente polarizadas en aplicaciones de tejidos utilizando células madre epiteliales que expresan lgr4, lgr5 y lgr6

Country Status (21)

Country Link
US (7) US10926001B2 (enExample)
EP (2) EP3227431B1 (enExample)
JP (3) JP6791854B2 (enExample)
KR (5) KR20210043024A (enExample)
CN (1) CN107250348B (enExample)
AU (3) AU2015355187C1 (enExample)
BR (1) BR112017011808A2 (enExample)
CA (1) CA2969707C (enExample)
CO (1) CO2017006640A2 (enExample)
CR (1) CR20170296A (enExample)
EA (1) EA201791125A1 (enExample)
GB (2) GB2549872A (enExample)
HK (1) HK1250515A1 (enExample)
IL (2) IL252613B (enExample)
MX (2) MX2017007243A (enExample)
MY (1) MY184931A (enExample)
NZ (2) NZ755260A (enExample)
PH (1) PH12017501009B1 (enExample)
SG (2) SG10201914058QA (enExample)
WO (1) WO2016089825A1 (enExample)
ZA (1) ZA201703907B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3595440A2 (en) * 2017-03-14 2020-01-22 Juno Therapeutics, Inc. Methods for cryogenic storage
CR20200366A (es) * 2018-01-26 2020-10-05 Polarityte Inc Sustrato acelarante de biomaterial con interfaz compuesta
AU2019212976A1 (en) * 2018-01-26 2020-07-23 Polarityte, Inc. Complex living interface-coordinated self-assembling materials (CLICSAM)
FR3082123B1 (fr) 2018-06-07 2020-10-16 Urgo Rech Innovation Et Developpement Pansement cellularise et son procede de fabrication
JP2024006681A (ja) * 2022-07-04 2024-01-17 学校法人近畿大学 生体材料
WO2025166131A1 (en) * 2024-02-01 2025-08-07 Board Of Regents, The University Of Texas System Compositions and methods for treating bone and muscle injuries

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126881A1 (en) * 2002-09-06 2004-07-01 Vincent Ronfard Fibrin cell supports and methods of use thereof
WO2006008009A2 (en) 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with leucine-rich repeat-containing gpcr 6 (lgr6)
US20060154365A1 (en) 2004-08-30 2006-07-13 Anthony Ratcliffe Cultured three dimensional tissues and uses thereof
EP1942957B1 (en) * 2005-10-27 2012-07-11 Coloplast A/S Biodegradable scaffold with ecm material
WO2008008009A1 (en) 2006-07-13 2008-01-17 St. Jude Medical Ab Medical information management in a patient information hub system
US8366723B2 (en) 2006-08-03 2013-02-05 Rassman Licensing, Llc Hair harvesting device and method with localized subsurface dermal fluid insertion
US7998737B2 (en) 2006-09-12 2011-08-16 Deutsches Krebsforschungszentrum Cell culture of keratinocytes under non-differentiating conditions
GB201111244D0 (en) 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
FI20095355A0 (fi) 2009-04-01 2009-04-01 Helsingin Yliopisto Regeneroituva aktiivinen matriisi ja sen käytöt
US20110076303A1 (en) 2009-06-25 2011-03-31 Tokuro Iwabuchi Methods for Screening for Anti-Graying Agents on the Basis of AFF-4
US20110130711A1 (en) 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
WO2012000180A1 (zh) 2010-06-30 2012-01-05 Chen Jinxi 一种皮肤组织细胞聚合物的制备方法及其用途
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
EP2771454B1 (en) 2011-10-27 2019-07-24 Universität Leipzig Method for deriving melanocytes from the hair follicle outer root sheath and preparation for grafting
JP6186997B2 (ja) 2012-08-07 2017-08-30 日油株式会社 塗布型帯電防止剤
US9655930B2 (en) 2012-10-01 2017-05-23 Aderans Research Institute, Inc. Compositions and methods for producing reconstituted skin
US20140106447A1 (en) 2012-10-12 2014-04-17 Mimedx Group, Inc. Compositions and methods for recruiting stem cells
CA3184040A1 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion comprising a wnt agonist and a histone deacetylase inhibitor
US9592257B2 (en) 2013-10-11 2017-03-14 MWV Cell, LLC Complete human skin organ generated from culture-expanded cells
CN103550828B (zh) * 2013-10-17 2016-01-27 中国科学院动物研究所 一种基于毛囊干细胞和硅凝胶敷料的皮肤重建方法
TWI548413B (zh) 2014-11-07 2016-09-11 國立臺灣大學 誘導毛囊新生的皮膚萃取物、組合物及其用途

Also Published As

Publication number Publication date
AU2019240603A1 (en) 2019-10-17
IL287488A (en) 2021-12-01
MX2023001655A (es) 2023-04-24
ZA201703907B (en) 2023-03-29
CO2017006640A2 (es) 2017-11-21
EP3227431A4 (en) 2019-01-02
JP6791854B2 (ja) 2020-11-25
AU2023202857A1 (en) 2023-05-25
US10926001B2 (en) 2021-02-23
AU2015355187B2 (en) 2019-10-03
EP4438128A2 (en) 2024-10-02
CA2969707A1 (en) 2016-06-09
IL252613A0 (en) 2017-07-31
GB201902819D0 (en) 2019-04-17
NZ733433A (en) 2019-08-30
US20220241464A1 (en) 2022-08-04
US20180154043A1 (en) 2018-06-07
MX2017007243A (es) 2018-01-25
GB201710646D0 (en) 2017-08-16
KR20180136588A (ko) 2018-12-24
AU2015355187C1 (en) 2020-02-20
US20190046691A1 (en) 2019-02-14
AU2015355187A1 (en) 2017-06-29
SG10201914058QA (en) 2020-03-30
US11596714B2 (en) 2023-03-07
KR20210043024A (ko) 2021-04-20
SG11201704502RA (en) 2017-06-29
GB2569056B (en) 2020-01-01
CN107250348A (zh) 2017-10-13
IL252613B (en) 2021-12-01
EP4438128A3 (en) 2024-11-13
US12465669B2 (en) 2025-11-11
WO2016089825A1 (en) 2016-06-09
CA2969707C (en) 2019-08-20
US20160151540A1 (en) 2016-06-02
US11266765B2 (en) 2022-03-08
EP3227431A1 (en) 2017-10-11
KR20190111167A (ko) 2019-10-01
EP3227431C0 (en) 2025-01-29
PH12017501009B1 (en) 2022-01-21
JP2020182880A (ja) 2020-11-12
US20230181797A1 (en) 2023-06-15
IL287488B2 (en) 2023-06-01
EA201791125A1 (ru) 2018-06-29
AU2019240603B2 (en) 2023-02-09
MY184931A (en) 2021-04-30
HK1245327A1 (zh) 2018-08-24
US20210322643A1 (en) 2021-10-21
HK1250515A1 (zh) 2018-12-21
US11000629B2 (en) 2021-05-11
KR20170098844A (ko) 2017-08-30
NZ755260A (en) 2021-12-24
US20180154044A1 (en) 2018-06-07
GB2549872A (en) 2017-11-01
JP2017538411A (ja) 2017-12-28
GB2569056A (en) 2019-06-05
BR112017011808A2 (pt) 2018-02-27
CN107250348B (zh) 2021-09-03
JP2019088299A (ja) 2019-06-13
EP3227431B1 (en) 2025-01-29
PH12017501009A1 (en) 2017-12-11
US11338060B2 (en) 2022-05-24
KR20180136587A (ko) 2018-12-24

Similar Documents

Publication Publication Date Title
CR20170296A (es) Métodos para el desarrollo y uso de unidades de micro-agregados de células funcionales mínimamente polarizadas en aplicaciones de tejidos utilizando células madre epiteliales que expresan lgr4, lgr5 y lgr6
CL2022003264A1 (es) Péptidos y sus combinaciones para uso en inmunoterapia contra el cáncer de próstata y otros
CL2019002940A1 (es) Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer. (divisional solicitud 201801531)
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
MX2021009673A (es) Moduladores de ror-gamma.
MX374472B (es) Composiciones y métodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
MX384175B (es) Métodos para seleccionar una línea de células t y el donador de la misma para terapia celular adoptiva.
MX2016010998A (es) Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
MX2017002382A (es) Metodos para tratar el mieloma multiple con compuestos imunomodulares en combinacion con anticuerpos.
MX2021012539A (es) Antagonistas de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita.
ZA202503350B (en) Semaglutide in medical therapy
MX2019012849A (es) Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
MX391949B (es) Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.
CL2019002942A1 (es) Nuevos péptidos y combinación para el uso en la inmunoterapia contra varios tipo de cáncer. (divisional solicitud 201801533)
MX386476B (es) Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo.
MX368735B (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
AR101582A1 (es) Tratamiento de tejido mamario con óxido nítrico
BR112016017012A2 (pt) Ensaio de potência para agentes terapêuticos
NZ744131A (en) Tumor-infiltrating lymphocytes for adoptive cell therapy
UA100842U (ru) Лекарственная композиция для тумесцентной анестезии